Lite Strategy

Lite Strategy Treasury Stock

The Treasury Stock of Lite Strategy (LITS) as of Nov 20, 2026 is 516.94 M USD. In the previous year, Treasury Stock was 421.10 M USD — a change of 22.76% (higher).

Treasury Stock

516.94 MUSD

YoY

22.76%

Last updated:

Treasury Stock of Lite Strategy is 2026 516.94 M USD. Treasury Stock of Lite Strategy was 2025 421.10 M USD. It decreases by 22.76% higher compared to the previous year.

The Lite Strategy Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2020
0.00 USD
Jan 1, 2021
369.17 M USD
Jan 1, 2022
426.57 M USD
Jan 1, 2023
430.62 M USD
Jan 1, 2024
421.24 M USD
Jan 1, 2025
421.10 M USD
Jan 1, 2026
516.94 M USD
The Lite Strategy Treasury Stock history
YEARTreasury StockYoY
516.94 MUSD+22.76%
421.10 MUSD-0.03%
421.24 MUSD-2.18%
430.62 MUSD+0.95%
426.57 MUSD+15.55%
369.17 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Treasury Stock of Lite Strategy is 516.94 M USD in 2026.

Treasury Stock of Lite Strategy changed from 421.10 M USD to 516.94 M USD, representing a 22.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Lite Strategy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lite Strategy

All Key Metrics — Lite Strategy